Contraindications for Enoxaparin (Lovenox) and Dexamethasone
Enoxaparin (Lovenox) - Absolute Contraindications
Enoxaparin is absolutely contraindicated in patients with active major bleeding, thrombocytopenia with positive anti-platelet antibodies in the presence of the drug, and known hypersensitivity to enoxaparin, heparin, or pork products 1.
The FDA-approved prescribing information specifies the following absolute contraindications 1:
- Active major bleeding at any site
- Thrombocytopenia with positive in vitro test for anti-platelet antibody in the presence of enoxaparin sodium (history of heparin-induced thrombocytopenia)
- Known hypersensitivity to enoxaparin sodium (including pruritus, urticaria, anaphylactic/anaphylactoid reactions)
- Known hypersensitivity to heparin or pork products
- Known hypersensitivity to benzyl alcohol (applies only to multi-dose formulation)
Enoxaparin - Situations Requiring Extreme Caution or Relative Contraindications
Use enoxaparin with extreme caution or avoid in patients with severe thrombocytopenia, uncontrollable active bleeding (except DIC), recent CNS bleeding, intracranial/spinal lesions at high risk for bleeding, and severe renal impairment 2, 3.
Additional high-risk situations from guidelines 2, 3:
- Severe renal impairment (creatinine clearance <30 mL/min) - requires dose adjustment to 1 mg/kg once daily for treatment or 30 mg once daily for prophylaxis 4, 5
- Liver failure with elevated INR >1.5
- Uncontrolled arterial hypertension (systolic >200 mmHg, diastolic >110 mmHg)
- Recent major operation at high risk for bleeding
- Severe platelet dysfunction (uremia, medications, dysplastic hematopoiesis)
- Platelet count <50,000/mcL for prophylactic anticoagulation 3
- Spinal anesthesia/lumbar puncture - enoxaparin should be used with extreme caution or discontinued before epidural administration 6
Special Population Considerations
Patients aged ≥70 years with renal insufficiency should not receive tinzaparin (a different LMWH), but enoxaparin can be used with appropriate dose adjustment 3.
For severe renal impairment (CrCl <30 mL/min): The standard enoxaparin dose is associated with 2-3 fold increased bleeding risk 4, 3. Dose must be reduced or alternative anticoagulant (UFH) considered 5.
Dexamethasone - Contraindications
While the provided evidence focuses primarily on enoxaparin, dexamethasone contraindications from general medical knowledge include:
- Active systemic fungal infections (absolute contraindication)
- Known hypersensitivity to dexamethasone or any component
- Live or live-attenuated vaccines should not be administered to patients receiving immunosuppressive doses
Dexamethasone - Use With Caution
- Active or latent tuberculosis
- Systemic infections (unless receiving specific anti-infective therapy)
- Ocular herpes simplex (risk of corneal perforation)
- Recent myocardial infarction (risk of myocardial rupture)
- Gastrointestinal disorders (peptic ulcer, diverticulitis, ulcerative colitis)
- Hypertension, heart failure, or recent MI
- Diabetes mellitus (causes hyperglycemia) 7
- Osteoporosis
- Myasthenia gravis
- Psychiatric disturbances
Critical Clinical Pitfalls
Never switch between enoxaparin and UFH or between different LMWHs - this significantly increases bleeding risk 8, 9.
Monitor platelet counts closely - check hemoglobin, hematocrit, and platelets every 2-3 days up to day 14, then every 2 weeks 3.
Neuraxial anesthesia warning: Epidural or spinal hematomas may occur with enoxaparin use during neuraxial anesthesia or spinal puncture, potentially causing permanent paralysis 1. Risk factors include indwelling epidural catheters, concomitant NSAIDs/antiplatelet agents, traumatic/repeated punctures, and spinal deformity.
Obesity considerations: Standard weight-based dosing (1 mg/kg) may be excessive in patients with BMI ≥40 kg/m², potentially requiring dose adjustment based on anti-Xa monitoring 10.